Blog · 2026-09-06 · 10 min
Davis et al. 2018: Persisting Effects After Clinic-Based Ibogaine Detox (Mixed-Methods Study)
Davis et al. 2018 mixed-methods study (n=73): persisting psychosocial effects after clinic-based ibogaine detox—oral≠IV; QTc; Schedule I.
Definition
Definition: Davis A.K., Renn E., Windham-Herman A.-M., Polanco M., & Barsuglia J.P. (2018) *A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification*, *Journal of Psychoactive Drugs* 50(4):287–297 (doi: 10.1080/02791072.2018.1487607; PMID 30020025). Secondary mixed-methods analysis from the same abroad clinic retrospective program as Davis/Barsuglia 2017: n=73 chronic opioid users compared as treatment responders vs non-responders, plus qualitative coding of open-ended persisting-effect themes (gratitude, meaning, sacredness, relational change, ongoing challenges). Route = clinic oral ibogaine detoxification context—not psychoactive IV ibogaine infusion. Observational; not RCT; not a cure claim; not approved for any indication. Ibogaine is U.S. Schedule I. QTc/cardiac risk remains central.
Short answer
Davis and colleagues’ 2018 Journal of Psychoactive Drugs mixed-method study (n=73) maps persisting psychosocial effects after clinic oral ibogaine detoxification. Themes are not controlled efficacy proof and not psychoactive IV ibogaine infusion evidence. Screen for QTc risk first.
Why this paper matters
Clinic detox outcomes are often described online through marketing case studies rather than peer-reviewed research. The Davis/Barsuglia clinic program secondary analysis is one of the few peer-reviewed sources that looks at what people report as lasting after clinic-based ibogaine detox—and at the challenges that remain. Next steps: /safety-and-screening → /apply.
Related observational papers: Schenberg Brazil series (/blog/ibogaine-stimulants-cocaine-literature), Malcolm 2018 (/blog/ibogaine-oud-case-series-2016-2020), and Mash 2018 N=191 (/blog/mash-2018-ibogaine-detox-frontiers).
What was studied
| Feature | Accurate description |
|---|---|
| Citation | Davis A.K., Renn E., Windham-Herman A.-M., Polanco M., Barsuglia J.P. *J Psychoactive Drugs*. 2018;50(4):287–297. doi **10.1080/02791072.2018.1487607**. PMID **30020025** |
| Type | Mixed-method secondary analysis (quantitative responder contrast + qualitative theme coding) |
| Parent cohort | Same abroad clinic retrospective survey family as Davis et al. 2017 |
| Analytic N | 73 (of 88 in the 2017 outcomes paper; 15 missing persisting-effects measures) |
| Route | **Oral** clinic ibogaine detoxification—not a psychoactive IV study |
| Focus | Persisting psychosocial effects linked to positive outcomes; challenges after detox |
| What it is not | RCT; urine-verified 12-month primary outcome; regulatory approval; IV proof; cardiac QT trial |
Methods (plain language)
Authors split participants into responders vs non-responders using opioid-use outcome definitions from the parent survey, then compared questionnaire scores and coded free-text answers about what felt lasting after detox. Qualitative themes help explain *how* people narrate benefit—they do not upgrade the design into a randomized trial.
Key findings (no hype)
- Responders more often described lasting gratitude, meaning, and sacred/spiritual framing of the detox experience.
- Open-ended answers also documented ongoing challenges (craving re-emergence, life stressors, incomplete psychosocial supports)—important anti-hype content.
- Mixed methods enrich the 2017 percentage headlines without proving causality.
- Authors situate results as hypothesis-generating for integration and aftercare research.
Honest reading: Clinic oral detox is experienced by many as psychologically “sticky”; stickiness ≠ lifelong cure and ≠ IV proof.
How it sits beside related detox observationals
| Paper | Distinct contribution |
|---|---|
| Davis/Barsuglia 2017 | n=88 subjective opioid use outcomes (/blog/davis-barsuglia-2017-ibogaine-survey) |
| **Davis 2018 mixed-method** | **Persisting psychosocial themes + responder contrast (n=73)** |
| Malcolm 2018 | Timed COWS/SOWS/BSCS n=50 (/blog/ibogaine-oud-case-series-2016-2020) |
| Brown & Alper 2018 | SOWS + ASI to 12 months (/blog/brown-alper-2018-ibogaine-oud) |
| Mash 2018 | Large open-label craving/mood N=191 (/blog/mash-2018-ibogaine-detox-frontiers) |
Cardiac safety gap
Persisting-effects psychology papers rarely carry QTc tables. Readers still need /blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-cardiovascular-complications-review, /blog/corkery-ibogaine-fatalities, and /safety-and-screening. Clinic observation abroad ≠ approved U.S. clinic.
Route honesty & entity clarity
Oral clinic detox narratives ≠ physician-supervised psychoactive IV ibogaine infusion. Supportive IV fluids/magnesium ≠ psychoactive IV ibogaine (/blog/ibogaine-oral-vs-iv; /blog/electrolytes-support-iv-vs-psychoactive-iv).
Limits and confounders
| Limit | Why it matters |
|---|---|
| Secondary analysis | Depends on parent survey biases |
| Self-selected responders | May over-represent positive narrators |
| No randomization | Setting and aftercare confound |
| Qualitative coding | Themes are interpretive, not effect sizes |
| Cardiac not primary | Incomplete risk picture alone |
What this does NOT prove for IV ibogaine infusion
| Claim | Status |
|---|---|
| “This study proves clinic detox cures OUD” | **False** (observational responder analysis, not a cure claim) |
| “Proves psychoactive IV ibogaine” | **False** |
| Useful labeled oral detox psychosocial signal? | **Yes—with method class stated** |
What “persisting effects” means in plain language
Clinic patients often describe ibogaine detox as more than a quiet medication day: autobiographical material, spiritual framing, interpersonal resolve, and a sense that something “stuck.” Davis 2018’s mixed-method design tries to catalog those narratives systematically—comparing people who met responder definitions on opioid outcomes with those who did not, then coding open text for recurring themes.
That is valuable for integration and aftercare design (/blog/ibogaine-aftercare-integration). It is not a license to market “permanent personality upgrades” or to imply that psychosocial stickiness removes cardiac risk.
Aftercare reminder tied to this paper
If gratitude and meaning rise while housing, trauma care, and contingency management are absent, relapse risk remains. Pair this article with longer observational durability papers (Brown/Noller) and with honest AE/fatality literacy (/blog/ona-2022-ibogaine-adverse-events-review). Programs abroad still require screening rigor comparable to any elective psychoactive exposure.
Misleading claims to watch for
- “New study proves ibogaine detox works.” (Observational mixed-methods design cannot prove that.)
- “73 patients cured—science confirms.” (Responder contrasts ≠ cures.)
- “IV infusion delivers the same persisting effects.” (Psychoactive IV route was not studied.)
Next steps
Meaning-making after detox is not a cardiac screen. Start: /safety-and-screening → /apply.
FAQ
What did Davis et al. 2018 study? Persisting psychosocial effects reported by 73 people after clinic-based oral ibogaine detox, comparing treatment responders with non-responders.
What is the DOI? **10.1080/02791072.2018.1487607** (PMID **30020025**).
Is it an RCT? No. Mixed-method observational secondary analysis.
Was the route IV ibogaine? No—clinic oral detox context.
Does gratitude prove efficacy? No. Themes describe experience; they do not replace controlled trials.
Does this erase cardiac risk? No.
Is ibogaine approved for medical use? No. Schedule I.
Where should screening start? /safety-and-screening → /apply.
Sources (selected)
- Davis A.K. et al. *J Psychoactive Drugs*. 2018. doi: 10.1080/02791072.2018.1487607. PMID: 30020025.
- Davis A.K. et al. *J Psychedelic Stud*. 2017. doi: 10.1556/2054.01.2017.009.
- Malcolm B.J. et al. *J Psychoactive Drugs*. 2018. doi: 10.1080/02791072.2018.1447175.
- Brown T.K., Alper K. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802.
- Mash D.C. et al. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
- Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
- 21 CFR 1308.11 — ibogaine Schedule I (United States).
Medical disclaimer
Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.
Davis 2018 is a mixed-method oral clinic detox analysis—not a cure claim and not psychoactive IV ibogaine efficacy proof.